Search

Displaying results 2651 - 2660 of 2955 in total
  1. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228773, L31578] Scopolamine was first approved by the FDA on December 31, 1979, and is currently available as both oral tablets and a transdermal delivery system.[L31578]

  2. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple

  3. Drug

    Cyproterone acetate

    go.drugbank.com/drugs/DB04839
    ApprovedInvestigational

    An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estroge...

    Mixtures: ESTELLE-35 ED TABLET
  4. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines

  5. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation.

  6. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099].

    Synonyms: -bis(disulfide) with immunoglobulin Fcab anti-(human type 1 transferrin receptor) (synthetic hu, - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, T
  7. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    [A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL.

  8. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    [L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000]

  9. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] This drug was approved by the FDA on April 26, 2022.[L41645]

  10. Drug

    Ivosidenib

    go.drugbank.com/drugs/DB14568
    ApprovedInvestigational

    [A248745] Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults.